The purpose of this study is to compare the efficacy and safety of 9MW2821 versus investigator's choice of chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer who have previously received taxane-based chemotherapy with or without immunotherapy and an antibody-drug conjugate with a topoisomerase inhibitor payload
Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.
Male or female subjects aged 18 to 75 years (including 18 and 75 years).
ECOG 0-1.
Histopathological diagnosed triple-negative breast cancer.
Preexisting treatment related toxicity Grade ≥ 2 and Grade ≥ 3 immune related adverse reactions.
Preexisting peripheral neuropathy Grade ≥ 2.
Hemoglobin A1C (HbA1c) ≥ 8%.
Has ocular conditions or symptoms that may increase the risk of the study.